ReviewThe American journal of medicine2008
Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug.
Review in The American journal of medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 60 citations in OpenAlex.
- Trial
- Mathematical modelling of the influence ofHeliyon · 2024Article
- First-line diuretics versus other classes of antihypertensive drugs for hypertension.The Cochrane database of systematic reviews · 2023Review
- Nanoformulations of flavonoids for diabetes and microvascular diabetic complications.Drug delivery and translational research · 2023Review
- NADPH Oxidase Inhibition in Fibrotic Pathologies.Antioxidants & redox signaling · 2020Article
- Role of the Angiotensin Pathway and its Target Therapy in Epilepsy Management.International journal of molecular sciences · 2019Review
- Benchmarking renin suppression and blood pressure reduction of direct renin inhibitor imarikiren through quantitative systems pharmacology modeling.Journal of pharmacokinetics and pharmacodynamics · 2019Article
- Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?Hypertension research : official journal of the Japanese Society of Hypertension · 2017Review
- Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.Science translational medicine · 2017Review
- Nanomedicines for Endothelial Disorders.Nano today · 2015Article
- Aliskiren restores renal AQP2 expression during unilateral ureteral obstruction by inhibiting the inflammasome.American journal of physiology. Renal physiology · 2015Article
- Mitral valve disease in Marfan syndrome and related disorders.Journal of cardiovascular translational research · 2011Review
- Functional sympatholysis is impaired in hypertensive humans.The Journal of physiology · 2011Article
- Renal protective effect of renin inhibition.Current hypertension reports · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The first oral direct renin inhibitor, aliskiren, recently received approval for the treatment of hypertension. This article addresses the premise, promise, and potential limitations of this new class of renin-angiotensin system inhibitor. Although aliskiren adds to a list of more than 100 drugs approved for the treatment of hypertension, its introduction into clinical medicine is of particular interest because of the novel mechanism of action: inhibition of renin's catalytic activity, the most proximal and rate-limiting step in renin-angiotensin system activation. By producing more complete renin-angiotensin system inhibition than with existing agents, direct renin inhibitors may afford greater protection from hypertensive complications. Other potential advantages include additional blood pressure reduction when used in combination therapy, a placebo-like side-effect profile, avid renal concentration, and long duration of action. Potential limitations include modest levels of blood pressure reduction that are equivalent to but not greater than angiotensin receptor blockers, reduced gastrointestinal absorption with a high-fat meal, and large reactive increases in renin secretion--the functional importance of which is under intense investigation. The results of outcomes trials are eagerly awaited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.